User login
Article Type
Changed
Thu, 12/15/2022 - 18:23
Display Headline
Anastrozole and Fulvestrant in Hormone Receptor-Positive Breast Cancer
SAN ANTONIO – Dr. William J. Gradishar and Dr. Hope S. Rugo, associate editors of The Oncology Report, discuss fulvestrant and anastrozole as first-line therapy for postmenopausal women with hormone receptor-positive breast cancer.
Topics
Legacy Keywords
fulvestrant breast cancer, anastrazole, postmenopausal women, hormone receptor-positive breast cancer, Dr. William J. Gradishar, Dr. Hope S. Rugo
SAN ANTONIO – Dr. William J. Gradishar and Dr. Hope S. Rugo, associate editors of The Oncology Report, discuss fulvestrant and anastrozole as first-line therapy for postmenopausal women with hormone receptor-positive breast cancer.
SAN ANTONIO – Dr. William J. Gradishar and Dr. Hope S. Rugo, associate editors of The Oncology Report, discuss fulvestrant and anastrozole as first-line therapy for postmenopausal women with hormone receptor-positive breast cancer.
Topics
Article Type
Display Headline
Anastrozole and Fulvestrant in Hormone Receptor-Positive Breast Cancer
Display Headline
Anastrozole and Fulvestrant in Hormone Receptor-Positive Breast Cancer
Legacy Keywords
fulvestrant breast cancer, anastrazole, postmenopausal women, hormone receptor-positive breast cancer, Dr. William J. Gradishar, Dr. Hope S. Rugo
Legacy Keywords
fulvestrant breast cancer, anastrazole, postmenopausal women, hormone receptor-positive breast cancer, Dr. William J. Gradishar, Dr. Hope S. Rugo
Article Source
PURLs Copyright
Inside the Article